世界の伝染病治療薬市場予測 2020年-2025年

【英語タイトル】Global Communicable Diseases Drugs Market Growth 2020-2025

LP Informationが出版した調査資料(LPI21MA03087)・商品コード:LPI21MA03087
・発行会社(調査会社):LP Information
・発行日:2021年1月
・ページ数:135
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野:医薬品・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥402,600見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥603,900見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥805,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
「伝染病治療薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、HIV、インフルエンザ、結核、マラリア、肝炎、HPVなど、用途別には、病院、診療所、その他などに区分してまとめた調査レポートです。伝染病治療薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が含まれています。
・伝染病治療薬の世界市場概要(サマリー)
・伝染病治療薬の企業別販売量・売上
・伝染病治療薬の企業別市場シェア
・伝染病治療薬の世界市場規模 2015年-2020年:種類別(HIV、インフルエンザ、結核、マラリア、肝炎、HPV)
・伝染病治療薬の世界市場規模 2015年-2020年:用途別(病院、診療所、その他)
・伝染病治療薬の米州市場規模(アメリカ、カナダ、メキシコなど)
・伝染病治療薬のアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・伝染病治療薬の欧州市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・伝染病治療薬の中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・伝染病治療薬市場の成長要因・課題・動向
・伝染病治療薬の世界市場予測 2021年-2025年
・伝染病治療薬の米州市場予測(アメリカ、カナダ、メキシコなど)
・伝染病治療薬のアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・伝染病治療薬の欧州市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・伝染病治療薬の中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・伝染病治療薬の世界市場予測:種類別(HIV、インフルエンザ、結核、マラリア、肝炎、HPV)
・伝染病治療薬の世界市場予測:用途別(病院、診療所、その他)
・主要企業分析
【レポートの概要】

According to this study, over the next five years the Communicable Diseases Drugs market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Communicable Diseases Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Communicable Diseases Drugs market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Communicable Diseases Drugs, covering the supply chain analysis, impact assessment to the Communicable Diseases Drugs market size growth rate in several scenarios, and the measures to be undertaken by Communicable Diseases Drugs companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
HIV
Influenza
TB
Malaria
Hepatitis
HPV

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Clinic
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Novartis
Gilead
Janssen Pharmaceutical
Roche
GSK
Boehringer Ingelheim
BioCryst Pharmaceuticals
Merck

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Communicable Diseases Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Communicable Diseases Drugs market by identifying its various subsegments.
Focuses on the key global Communicable Diseases Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Communicable Diseases Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Communicable Diseases Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Communicable Diseases Drugs Consumption 2015-2025
2.1.2 Communicable Diseases Drugs Consumption CAGR by Region
2.2 Communicable Diseases Drugs Segment by Type
2.2.1 HIV
2.2.2 Influenza
2.2.3 TB
2.2.4 Malaria
2.2.5 Hepatitis
2.2.6 HPV
2.3 Communicable Diseases Drugs Consumption by Type
2.3.1 Global Communicable Diseases Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Communicable Diseases Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Communicable Diseases Drugs Sale Price by Type (2015-2020)
2.4 Communicable Diseases Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Communicable Diseases Drugs Consumption by Application
2.5.1 Global Communicable Diseases Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Communicable Diseases Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Communicable Diseases Drugs Sale Price by Type (2015-2020)

3 Global Communicable Diseases Drugs by Company
3.1 Global Communicable Diseases Drugs Sales Market Share by Company
3.1.1 Global Communicable Diseases Drugs Sales by Company (2018-2020)
3.1.2 Global Communicable Diseases Drugs Sales Market Share by Company (2018-2020)
3.2 Global Communicable Diseases Drugs Revenue Market Share by Company
3.2.1 Global Communicable Diseases Drugs Revenue by Company (2018-2020)
3.2.2 Global Communicable Diseases Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Communicable Diseases Drugs Sale Price by Company
3.4 Global Communicable Diseases Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Communicable Diseases Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Communicable Diseases Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Communicable Diseases Drugs by Regions
4.1 Communicable Diseases Drugs by Regions
4.2 Americas Communicable Diseases Drugs Consumption Growth
4.3 APAC Communicable Diseases Drugs Consumption Growth
4.4 Europe Communicable Diseases Drugs Consumption Growth
4.5 Middle East & Africa Communicable Diseases Drugs Consumption Growth

5 Americas
5.1 Americas Communicable Diseases Drugs Consumption by Countries
5.1.1 Americas Communicable Diseases Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Communicable Diseases Drugs Value by Countries (2015-2020)
5.2 Americas Communicable Diseases Drugs Consumption by Type
5.3 Americas Communicable Diseases Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Communicable Diseases Drugs Consumption by Regions
6.1.1 APAC Communicable Diseases Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Communicable Diseases Drugs Value by Regions (2015-2020)
6.2 APAC Communicable Diseases Drugs Consumption by Type
6.3 APAC Communicable Diseases Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Communicable Diseases Drugs by Countries
7.1.1 Europe Communicable Diseases Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Communicable Diseases Drugs Value by Countries (2015-2020)
7.2 Europe Communicable Diseases Drugs Consumption by Type
7.3 Europe Communicable Diseases Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Communicable Diseases Drugs by Countries
8.1.1 Middle East & Africa Communicable Diseases Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Communicable Diseases Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Communicable Diseases Drugs Consumption by Type
8.3 Middle East & Africa Communicable Diseases Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Communicable Diseases Drugs Distributors
10.3 Communicable Diseases Drugs Customer

11 Global Communicable Diseases Drugs Market Forecast
11.1 Global Communicable Diseases Drugs Consumption Forecast (2021-2025)
11.2 Global Communicable Diseases Drugs Forecast by Regions
11.2.1 Global Communicable Diseases Drugs Forecast by Regions (2021-2025)
11.2.2 Global Communicable Diseases Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast byRegions
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Communicable Diseases Drugs Forecast by Type
11.8 Global Communicable Diseases Drugs Forecast by Application

12 Key Players Analysis
12.1 Novartis
12.1.1 Company Information
12.1.2 Communicable Diseases Drugs Product Offered
12.1.3 Novartis Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Novartis Latest Developments
12.2 Gilead
12.2.1 Company Information
12.2.2 Communicable Diseases Drugs Product Offered
12.2.3 Gilead Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Gilead Latest Developments
12.3 Janssen Pharmaceutical
12.3.1 Company Information
12.3.2 Communicable Diseases Drugs Product Offered
12.3.3 Janssen Pharmaceutical Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Janssen Pharmaceutical Latest Developments
12.4 Roche
12.4.1 Company Information
12.4.2 Communicable Diseases Drugs Product Offered
12.4.3 Roche Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Roche Latest Developments
12.5 GSK
12.5.1 Company Information
12.5.2 Communicable Diseases Drugs Product Offered
12.5.3 GSK Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 GSK Latest Developments
12.6 Boehringer Ingelheim
12.6.1 Company Information
12.6.2 Communicable Diseases Drugs Product Offered
12.6.3 Boehringer Ingelheim Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Boehringer Ingelheim Latest Developments
12.7 BioCryst Pharmaceuticals
12.7.1 Company Information
12.7.2 Communicable Diseases Drugs Product Offered
12.7.3 BioCryst Pharmaceuticals Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 BioCryst Pharmaceuticals Latest Developments
12.8 Merck
12.8.1 Company Information
12.8.2 Communicable Diseases Drugs Product Offered
12.8.3 Merck Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Merck Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Communicable Diseases Drugs Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of HIV
Table 5. Major Players of Influenza
Table 6. Major Players of TB
Table 7. Major Players of Malaria
Table 8. Major Players of Hepatitis
Table 9. Major Players of HPV
Table 10. Global Consumption Sales by Type (2015-2020)
Table 11. Global Communicable Diseases Drugs Consumption Market Share by Type (2015-2020)
Table 12. Global Communicable Diseases Drugs Revenue by Type (2015-2020) ($ million)
Table 13. Global Communicable Diseases Drugs Value Market Share by Type (2015-2020) ($ Millions)
Table 14. Global Communicable Diseases Drugs Sale Price by Type (2015-2020)
Table 15. Global Consumption Sales by Application (2015-2020)
Table 16. Global Communicable Diseases Drugs Consumption Market Share by Application (2015-2020)
Table 17. Global Communicable Diseases Drugs Value by Application (2015-2020)
Table 18. Global Communicable Diseases Drugs Value Market Share by Application (2015-2020)
Table 19. Global Communicable Diseases Drugs Sale Price by Application (2015-2020)
Table 20. Global Communicable Diseases Drugs Sales by Company (2017-2019) (K Units)
Table 21. Global Communicable Diseases Drugs Sales Market Share by Company (2017-2019)
Table 22. Global Communicable Diseases Drugs Revenue by Company (2017-2019) ($ Millions)
Table 23. Global Communicable Diseases Drugs Revenue Market Share by Company (2017-2019)
Table 24. Global Communicable Diseases Drugs Sale Price by Company (2017-2019)
Table 25. Global Communicable Diseases Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
Table 26. Players Communicable Diseases Drugs Products Offered
Table 27. Communicable Diseases Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 28. Global Communicable Diseases Drugs Consumption by Regions 2015-2020 (K Units)
Table 29. Global Communicable Diseases Drugs Consumption Market Share by Regions 2015-2020
Table 30. Global Communicable Diseases Drugs Value by Regions 2015-2020 ($ Millions)
Table 31. Global Communicable Diseases Drugs Value Market Share by Regions 2015-2020
Table 32. Americas Communicable Diseases Drugs Consumption by Countries (2015-2020) (K Units)
Table 33. Americas Communicable Diseases Drugs Consumption Market Share by Countries (2015-2020)
Table 34. Americas Communicable Diseases Drugs Value by Countries (2015-2020) ($ Millions)
Table 35. Americas Communicable Diseases Drugs Value Market Share by Countries (2015-2020)
Table 36. Americas Communicable Diseases Drugs Consumption by Type (2015-2020) (K Units)
Table 37. Americas Communicable Diseases Drugs Consumption Market Share by Type (2015-2020)
Table 38. Americas Communicable Diseases Drugs Consumption by Application (2015-2020) (K Units)
Table 39. Americas Communicable Diseases Drugs Consumption Market Share by Application (2015-2020)
Table 40. APAC Communicable Diseases Drugs Consumption by Regions (2015-2020) (K Units)
Table 41. APAC Communicable Diseases Drugs Consumption Market Share by Regions (2015-2020)
Table 42. APAC Communicable Diseases Drugs Value by Regions (2015-2020) ($ Millions)
Table 43. APAC Communicable Diseases Drugs Value Market Share by Regions (2015-2020)
Table 44. APAC Communicable Diseases Drugs Consumption by Type (2015-2020) (K Units)
Table 45. APAC Communicable Diseases Drugs Consumption Market Share by Type (2015-2020)
Table 46. APAC Communicable Diseases Drugs Consumption by Application (2015-2020) (K Units)
Table 47. APAC Communicable Diseases Drugs Consumption Market Share by Application (2015-2020)
Table 48. Europe Communicable Diseases Drugs Consumption by Countries (2015-2020) (K Units)
Table 49. Europe Communicable Diseases Drugs Consumption Market Share by Countries (2015-2020)
Table 50. Europe Communicable Diseases Drugs Value by Countries (2015-2020) ($ Millions)
Table 51. Europe Communicable Diseases Drugs Value Market Share by Countries (2015-2020)
Table 52. Europe Communicable Diseases Drugs Consumption by Type (2015-2020) (K Units)
Table 53. Europe Communicable Diseases Drugs Consumption Market Share by Type (2015-2020)
Table 54. Europe Communicable Diseases Drugs Consumption by Application (2015-2020) (K Units)
Table 55. Europe Communicable Diseases Drugs Consumption Market Share by Application (2015-2020)
Table 56. Middle East & Africa Communicable Diseases Drugs Consumption by Countries (2015-2020) (K Units)
Table 57. Middle East & Africa Communicable Diseases Drugs Consumption Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Communicable Diseases Drugs Value by Countries (2015-2020) ($ Millions)
Table 59. Middle East & Africa Communicable Diseases Drugs Value Market Share by Countries (2015-2020)
Table 60. Middle East & Africa Communicable Diseases Drugs Consumption by Type (2015-2020) (K Units)
Table 61. Middle East & Africa Communicable Diseases Drugs Consumption Market Share by Type (2015-2020)
Table 62. Middle East & Africa Communicable Diseases Drugs Consumption by Application (2015-2020) (K Units)
Table 63. Middle East & Africa Communicable Diseases Drugs Consumption Market Share by Application (2015-2020)
Table 64. Communicable Diseases Drugs Distributors List
Table 65. Communicable Diseases Drugs Customer List
Table 66. Global Communicable Diseases Drugs Consumption Forecast by Countries (2021-2025) (K Units)
Table 67. Global Communicable Diseases Drugs Consumption Market Forecast by Regions
Table 68. Global Communicable Diseases Drugs Value Forecast by Countries (2021-2025) ($ Millions)
Table 69. Global Communicable Diseases Drugs Value Market Share Forecast by Regions
Table 70. Global Communicable Diseases Drugs Consumption Forecast by Type (2021-2025) (K Units)
Table 71. Global Communicable Diseases Drugs Consumption Market Share Forecast by Type (2021-2025)
Table 72. Global Communicable Diseases Drugs Value Forecast by Type (2021-2025) ($ Millions)
Table 73. Global Communicable Diseases Drugs Value Market Share Forecast by Type (2021-2025)
Table 74. Global Communicable Diseases Drugs Consumption Forecast by Application (2021-2025) (K Units)
Table 75. Global Communicable Diseases Drugs Consumption Market Share Forecast by Application (2021-2025)
Table 76. Global Communicable Diseases Drugs Value Forecast by Application (2021-2025) ($ Millions)
Table 77. Global Communicable Diseases Drugs Value Market Share Forecast by Application (2021-2025)
Table 78. Novartis Product Offered
Table 79. Novartis Communicable Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 80. Novartis Main Business
Table 81. Novartis Latest Developments
Table 82. Novartis Basic Information, Company Total Revenue (in $ million), Communicable Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Gilead Product Offered
Table 84. Gilead Communicable Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 85. Gilead Main Business
Table 86. Gilead Latest Developments
Table 87. Gilead Basic Information, Company Total Revenue (in $ million), Communicable Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Janssen Pharmaceutical Product Offered
Table 89. Janssen Pharmaceutical Communicable Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 90. Janssen Pharmaceutical Main Business
Table 91. Janssen Pharmaceutical Latest Developments
Table 92. Janssen Pharmaceutical Basic Information, Company Total Revenue (in $ million), Communicable Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Roche Product Offered
Table 94. Roche Communicable Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 95. Roche Main Business
Table 96. Roche Latest Developments
Table 97. Roche Basic Information, Company Total Revenue (in $ million), Communicable Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. GSK Product Offered
Table 99. GSK Communicable Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 100. GSK Main Business
Table 101. GSK Latest Developments
Table 102. GSK Basic Information, Company Total Revenue (in $ million), Communicable Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Boehringer Ingelheim Product Offered
Table 104. Boehringer Ingelheim Communicable Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 105. Boehringer Ingelheim Main Business
Table 106. Boehringer Ingelheim Latest Developments
Table 107. Boehringer Ingelheim Basic Information, Company Total Revenue (in $ million), Communicable Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. BioCryst Pharmaceuticals Product Offered
Table 109. BioCryst Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Communicable Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. BioCryst Pharmaceuticals Main Business
Table 111. BioCryst Pharmaceuticals Latest Developments
Table 112. BioCryst Pharmaceuticals Communicable Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 113. Merck Product Offered
Table 114. Merck Communicable Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 115. Merck Main Business
Table 116. Merck Latest Developments
Table 117. Merck Basic Information, Company Total Revenue (in $ million), Communicable Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Communicable Diseases Drugs
Figure 2. Communicable Diseases Drugs Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Communicable Diseases Drugs Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Communicable Diseases Drugs Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of HIV
Figure 7. Product Picture of Influenza
Figure 8. Product Picture of TB
Figure 9. Product Picture of Malaria
Figure 10. Product Picture of Hepatitis
Figure 11. Product Picture of HPV
Figure 12. Global Communicable Diseases Drugs Consumption Market Share by Type (2015-2020)
Figure 13. Global Communicable Diseases Drugs Value Market Share by Type (2015-2020)
Figure 14. Communicable Diseases Drugs Consumed in Hospital
Figure 15. Global Communicable Diseases Drugs Market: Hospital (2015-2020) (K Units)
Figure 16. Global Communicable Diseases Drugs Market: Hospital (2015-2020) ($ Millions)
Figure 17. Communicable Diseases Drugs Consumed in Clinic
Figure 18. Global Communicable Diseases Drugs Market: Clinic (2015-2020) (K Units)
Figure 19. Global Communicable Diseases Drugs Market: Clinic (2015-2020) ($ Millions)
Figure 20. Communicable Diseases Drugs Consumed in Other
Figure 21. Global Communicable Diseases Drugs Market: Other (2015-2020) (K Units)
Figure 22. Global Communicable Diseases Drugs Market: Other (2015-2020) ($ Millions)
Figure 23. Global Communicable Diseases Drugs Consumption Market Share by Application (2015-2020)
Figure 24. Global Communicable Diseases Drugs Value Market Share by Application (2015-2020)
Figure 25. Global Communicable Diseases Drugs Sales Market Share by Company in 2017
Figure 26. Global Communicable Diseases Drugs Sales Market Share by Company in 2019
Figure 27. Global Communicable Diseases Drugs Revenue Market Share by Company in 2017
Figure 28. Global Communicable Diseases Drugs Revenue Market Share by Company in 2019
Figure 29. Global Communicable Diseases Drugs Sale Price by Company in 2019
Figure 30. Global Communicable Diseases Drugs Consumption Market Share by Regions 2015-2020
Figure 31. Global Communicable Diseases Drugs Value Market Share by Regions 2015-2020
Figure 32. Americas Communicable Diseases Drugs Consumption 2015-2020 (K Units)
Figure 33. Americas Communicable Diseases Drugs Value 2015-2020 ($ Millions)
Figure 34. APAC Communicable Diseases Drugs Consumption 2015-2020 (K Units)
Figure 35. APAC Communicable Diseases Drugs Value 2015-2020 ($ Millions)
Figure 36. Europe Communicable Diseases Drugs Consumption 2015-2020 (K Units)
Figure 37. Europe Communicable Diseases Drugs Value 2015-2020 ($ Millions)
Figure 38. Middle East & Africa Communicable Diseases Drugs Consumption 2015-2020 (K Units)
Figure 39. Middle East & Africa Communicable Diseases Drugs Value 2015-2020 ($ Millions)
Figure 40. Americas Communicable Diseases Drugs Consumption Market Share by Countries in 2019
Figure 41. Americas Communicable Diseases Drugs Value Market Share by Countries in 2019
Figure 42. Americas Communicable Diseases Drugs Consumption Market Share by Type in 2019
Figure 43. Americas Communicable Diseases Drugs Consumption Market Share by Application in 2019
Figure 44. United States Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 45. United States Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 46. Canada Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 47. Canada Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 48. Mexico Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 49. Mexico Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 50. APAC Communicable Diseases Drugs Consumption Market Share by Countries in 2019
Figure 51. APAC Communicable Diseases Drugs Value Market Share by Regions in 2019
Figure 52. APAC Communicable Diseases Drugs Consumption Market Share by Type in 2019
Figure 53. APAC Communicable Diseases Drugs Consumption Market Share by Application in 2019
Figure 54. China Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 55. China Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 56. Japan Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 57. Japan Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 58. Korea Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 59. Korea Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 60. Southeast Asia Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 61. Southeast Asia Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 62. India Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 63. India Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 64. Australia Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 65. Australia Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 66. Europe Communicable Diseases Drugs Consumption Market Share by Countries in 2019
Figure 67. Europe Communicable Diseases Drugs Value Market Share by Countries in 2019
Figure 68. Europe Communicable Diseases Drugs Consumption Market Share by Type in 2019
Figure 69. Europe Communicable Diseases Drugs Consumption Market Share by Application in 2019
Figure 70. Germany Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 71. Germany Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 72. France Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 73. France Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 74. UK Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 75. UK Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 76. Italy Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 77. Italy Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 78. Russia Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 79. Russia Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 80. Middle East & Africa Communicable Diseases Drugs Consumption Market Share by Countries in 2019
Figure 81. Middle East & Africa Communicable Diseases Drugs Value Market Share by Countries in 2019
Figure 82. Middle East & Africa Communicable Diseases Drugs Consumption Market Share by Type in 2019
Figure 83. Middle East & Africa Communicable Diseases Drugs Consumption Market Share by Application in 2019
Figure 84. Egypt Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 85. Egypt Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 86. South Africa Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 87. South Africa Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 88. Israel Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 89. Israel Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 90. Turkey Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 91. Turkey Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 92. GCC Countries Communicable Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 93. GCC Countries Communicable Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 94. Global Communicable Diseases Drugs Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 95. Global Communicable Diseases Drugs Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 96. Americas Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 97. Americas Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 98. APAC Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 99. APAC Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 100. Europe Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 101. Europe Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 102. Middle East & Africa Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 103. Middle East & Africa Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 104. United States Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 105. United States Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 106. Canada Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 107. Canada Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 108. Mexico Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 109. Mexico Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 110. Brazil Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 111. Brazil Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 112. China Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 113. China Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 114. Japan Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 115. Japan Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 116. Korea Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 117. Korea Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 118. Southeast Asia Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 119. Southeast Asia Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 120. India Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 121. India Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 122. Australia Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 123. Australia Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 124. Germany Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 125. Germany Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 126. France Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 127. France Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 128. UK Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 129. UK Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 130. Italy Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 131. Italy Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 132. Russia Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 133. Russia Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 134. Spain Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 135. Spain Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 136. Egypt Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 137. Egypt Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 138. South Africa Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 139. South Africa Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 140. Israel Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 141. Israel Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 142. Turkey Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 143. Turkey Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 144. GCC Countries Communicable Diseases Drugs Consumption 2021-2025 (K Units)
Figure 145. GCC Countries Communicable Diseases Drugs Value 2021-2025 ($ Millions)
Figure 146. Novartis Communicable Diseases Drugs Market Share (2018-2020)
Figure 147. Gilead Communicable Diseases Drugs Market Share (2018-2020)
Figure 148. Janssen Pharmaceutical Communicable Diseases Drugs Market Share (2018-2020)
Figure 149. Roche Communicable Diseases Drugs Market Share (2018-2020)
Figure 150. GSK Communicable Diseases Drugs Market Share (2018-2020)
Figure 151. Boehringer Ingelheim Communicable Diseases Drugs Market Share (2018-2020)
Figure 152. BioCryst Pharmaceuticals Communicable Diseases Drugs Market Share (2018-2020)
Figure 153. Merck Communicable Diseases Drugs Market Share (2018-2020)


★調査レポート[世界の伝染病治療薬市場予測 2020年-2025年] (コード:LPI21MA03087)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の伝染病治療薬市場予測 2020年-2025年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆